TherapeuticsMD (NYSE: TXMD) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $4.65 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.